Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT).

Vincent T. Ho, MD, Haesook Kim, PhD, Shuli Li, MS, Corey Cutler, MD MPH, John Koreth, MBBS, Phillipe Armand, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD, Edwin P. Alyea, MD

Blood (2007) 110 (11): 3046.

https://doi.org/10.1182/blood.V110.11.3046.3046

Published: 2007

Journal Articles

Long-Term Outcome of Methotrexate-Free GVHD Prophylaxis Using Sirolimus and Tacrolimus in Matched Related (MRD) and Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation (PBSCT).

Corey Cutler, MD, MPH, FRCP, Shuli Li, MS, Vincent Ho, MD, John Koreth, MBBS, Edwin Alyea, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD

Blood (2006) 108 (11): 757.

https://doi.org/10.1182/blood.V108.11.757.757

Published: 2006

Journal Articles

Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Unrelated Peripheral Blood Stem Cell Transplantation: Excellent GVHD Control with Low Transplant-Related Morbidity and Mortality.

Corey Cutler, MD, MPH, FRCP(C), Shuli Li, MS, Haesook T. Kim, PhD, Rebecca Macdonell, Vincent Ho, MD, Edwin Alyea, MD, Stephanie J. Lee, MD, MPH, Robert J. Soiffer, MD, Joseph H. Antin, MD

Blood (2005) 106 (11): 2051.

https://doi.org/10.1182/blood.V106.11.2051.2051

Published: 2005

Journal Articles

Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.

Corey Cutler, MD MPH FRCPC, Shuli Li, MS, Haesook T. Kim, PhD, Edwin Alyea, MD, Vincent Ho, MD, Stephanie J. Lee, MD MPH, David C. Fisher, MD, Robert Schlossman, MD, David Miklos, MD PhD, Stephen Sonis, DMD DMSc, Robert Soiffer, MD, Joseph H. Antin, MD

Blood (2004) 104 (11): 1227.

https://doi.org/10.1182/blood.V104.11.1227.1227

Published: 2004

Journal Articles

Sirolimus and Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation.

N. Lynn Henry, MD, Shuli Li, MS, Haesook T. Kim, PhD, Colm Magee, MD MPH, Edwin Alyea, MD, Vincent Ho, MD, Stephanie J. Lee, MD MPH, Robert Soiffer, MD, Joseph H. Antin, MD, Corey Cutler, MD MPH FRCPC

Blood (2004) 104 (11): 1834.

https://doi.org/10.1182/blood.V104.11.1834.1834

Published: 2004

Journal Articles

High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.

Edwin P. Alyea, MD, Shuli Li, MS, Haesook Kim, PhD, Vincent T. Ho, MD, Corey Cutler, MD, Stephanie J. Lee, MD, John Gribben, MD, Richard M. Stone, MD, Daniel J. DeAngelo, MD, Jerome Ritz, MD, Joseph H. Antin, MD, Robert J. Soiffer, MD

Blood (2004) 104 (11): 185.

https://doi.org/10.1182/blood.V104.11.185.185

Published: 2004

Journal Articles

Sirolimus, Tacrolimus and Reduced-Dose Methotrexate as Graft Versus Host Disease (GVHD)Prophylaxis after Non-Myeloablative Stem Cell Transplantation: Low Incidence of Acute GVHD Compared with Tacrolimus/Methotrexate or Cyclosporine/Prednisone.

Edwin P. Alyea, MD, Shuli Li, MS, Haesook Kim, PhD, Corey Cutler, MD, Vincent Ho, MD, Stephanie J. Lee, MD, John Gribben, MD, PhD, Jerome Ritz, MD, David C. Fisher, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD

Blood (2004) 104 (11): 730.

https://doi.org/10.1182/blood.V104.11.730.730

Published: 2004

Journal Articles

Patterns of Growth Factor (GF) Usage and Febrile Neutropenia (FN) among Older Patients (pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP or R-CHOP: An Intergroup Experience (CALGB 9793, ECOG-SWOG 4494).

Vicki A. Morrison, MD, Edie A. Weller, PhD, Thomas M. Habermann, MD, Shuli Li, MS, Sandra J. Horning, MD, Richard I. Fisher, MD, Bruce A. Peterson, MD

Blood (2004) 104 (11): 3309.

https://doi.org/10.1182/blood.V104.11.3309.3309

Published: 2004

Journal Articles

Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.

Corey Cutler, MD, MPH, FRCPC, Shuli Li, MS, Haesook T. Kim, PhD, Edwin Alyea, MD, Vincent Ho, MD, Stephanie J. Lee, MD, MPH, David C. Fisher, MD, Robert Schlossman, MD, David Miklos, MD, Robert Soiffer, MD, Joseph H. Antin, MD

Blood (2004) 104 (11): 3317.

https://doi.org/10.1182/blood.V104.11.3317.3317

Published: 2004

Journal Articles

Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.

Corey Cutler, MD MPH FRCPC, Shuli Li, MS, Haesook T. Kim, PhD, Patricia Laglenne, MS RD, Colleen Ford, Vincent Ho, MD, Stephanie J. Lee, MD MPH, Edwin Alyea, MD, Robert Soiffer, MD, Joseph H. Antin, MD, Stephen Sonis, DMD DMSc

Blood (2004) 104 (11): 351.

https://doi.org/10.1182/blood.V104.11.351.351

Published: 2004

NARROW

Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT).

Long-Term Outcome of Methotrexate-Free GVHD Prophylaxis Using Sirolimus and Tacrolimus in Matched Related (MRD) and Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation (PBSCT).

Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Unrelated Peripheral Blood Stem Cell Transplantation: Excellent GVHD Control with Low Transplant-Related Morbidity and Mortality.

Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.

Sirolimus and Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation.

High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.

Sirolimus, Tacrolimus and Reduced-Dose Methotrexate as Graft Versus Host Disease (GVHD)Prophylaxis after Non-Myeloablative Stem Cell Transplantation: Low Incidence of Acute GVHD Compared with Tacrolimus/Methotrexate or Cyclosporine/Prednisone.

Patterns of Growth Factor (GF) Usage and Febrile Neutropenia (FN) among Older Patients (pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP or R-CHOP: An Intergroup Experience (CALGB 9793, ECOG-SWOG 4494).

Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.

Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only